Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline

Impact · against what's priced in

Tarsus Pharmaceuticals expands its pipeline into the retina market through the acquisition of iRenix and its candidate IRX-101. The deal adds a late-stage asset targeting a high-volume market of 11 million annual injections with a clear path to Phase III in 2027 and relatively low development costs of $20M-$30M.

TARS+0.30

No priced-in read yet

In context

The acquisition of iRenix introduces IRX-101, a late-stage antiseptic for intravitreal injections, expanding Tarsus' reach into a market of 11 million annual US procedures with patent protection extending to 2039.

Read from the article alone

• TARS

Search tags